Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations' SynoGraph™ oncology platform. The project, titled "Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data," will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data. This collaboration marks a significant step in applying advanced AI to oncology research, with the potential to accelerate drug development and reduce failure rates in clinical trials.
Redwood AI, developer of an AI-powered platform for real-world applications across multiple critical industries, will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph's predictive capabilities. The project is led by Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ), with Redwood AI, the Michael Smith Genome Sciences Centre, and the Centre de recherche du CHU de Québec-Université Laval as co-applicants. The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy.
The involvement of Redwood AI in this consortium underscores the growing importance of AI in oncology and the company's expanding role in critical research. By integrating its expertise in data and chemical modelling, Redwood AI is positioned to help address one of the most challenging aspects of cancer drug development: predicting how treatments will perform in humans based on preclinical data. This could lead to more efficient and targeted clinical trials, ultimately benefiting patients and reducing costs for developers. The collaboration also highlights the value of public-private partnerships in advancing medical innovation.
Investors and stakeholders can find more information about Redwood AI on the Redwood AI Corp. profile page, and the full announcement is available in the Read More>> article on AINewsWire. The latest news and updates relating to RDWCF are available in the company's newsroom at https://ibn.fm/RDWCF.
As a specialized communications platform focused on artificial intelligence, AINewsWire disseminates news like this through its extensive network. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, AINW brings its clients unparalleled recognition and brand awareness. AINW is where breaking news, insightful content and actionable information converge.
